IQVIA™ Real-World Insights Bibliography

Patient and caregiver indirect costs after acute cardiovascular events in Europe.
Author(s): Sidelnikov E1, Gerlier L2, Kutikova L1, Amarenco P3, Kotseva K4, Annemans L5
Affiliations(s): 1 Amgen (Europe) GmbH, Zug, Switzerland 2 IQVIA, Zaventem, Belgium 3 Paris-Diderot-Sorbonne University, Paris, France 4 National Heart & Lung Institute, Imperial College London, London, UK 5 Ghent University, Ghent, Belgium
Publication(s):  ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain
Document Type(s): Oral presentation,
Countries: Austria, Bulgaria, Croatia, Czech, Denmark, Finland, Germany, Greece, Italy, Norway, Romania, Slovakia, Slovenia,
Click here for the abstract
C:
Y:
Cardiovascular disease, Health economics,
2018
  L:
A:
English
Burden of illness, Cost of illness,
  Add to report
 
 
Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature.
Author(s): Svedman FC1, Pillas D2, Taylor A2, Kaur M2, Linder R3, Hansson J1.
Affiliations(s): 1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden. 2Centre for Observational Research, Amgen Ltd, Uxbridge, UK. 3IMS Health Sweden, Stockholm, Sweden.
Publication(s):  Clinical Epidemiology
Document Type(s): Article,
Countries: Australia, Austria, Belgium, Bulgaria, Croatia, Czech, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK,
Click here for the abstract
C:
Y:
Oncology,
2016
  L:
A:
English
Literature Review,
  Add to report
 
 
Cost analysis: treatment of chemotherapy-induced anemia with erythropoiesis-stimulating agents in five European countries
Author(s): Duran A1, Spaepen E2,Lamotte M3, Walter E4, Umuhire D5, Lucioni C6, Pinheir B7, Brosa M8, Pujol LKB9, Van Belle S10, Annemans L11
Affiliations(s): 1 IMS Health, London, UK 2 SBD Analytics BVBA/SPRL, Bekkevoort, Belgium 3 IMS Health, Vilvoorde, Belgium 4 Institute for Pharmaeconomic Research, Health Economics, Vienna, Austria 5 IMS Health, Paris, France 6 Wolters Kluwer Health Italy, Milan, Italy 7 CISEP, Research Centre on the Portuguese Economy, Lisbon, Portugal 8 Oblikue Consulting, Barcelona, Spain 9 Amgen (Europe) GmbH, Zug, Switzerland 10 Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium 11 I-CHER, Ghent University, Brussels University (VUB), Ghent, Belgium
Publication(s):  Journal of Medical Economics Vol. 15, No. 3, 2012, 1?10
Document Type(s): Article,
Countries: Austria, Belgium, France, Italy, Spain,
C:
Y:
Hematology,
2012
  L:
A:
English
Cost analysis,
  Add to report
 
 
Cost analysis of anemia treatment with erythropoieses-stimulating agents (ESAs) in patients with cancer receiving chemotherapy: a multi-country approach.
Author(s): Duran A1, Spaepen E2, Lamotte M3, Walter E4, Lucioni C5, Pinheiro B6, Brosa M7, Kutikova L8, Pujol B8, Annemans L9
Affiliations(s): 1 IMS Health, London, United Kingdom 2 SBD Analytics, Belgium 3 IMS Health, Vilvoorde, Belgium 4 Institute for Parmacoeconomic Research, Vienna, Austria 5 Wolters Kluwer Health Italy, Milan, Italy 6 Centre de Investigaçao Sobre Economia Portuguesa, Lisboa, Portugal 7 Oblikue Consulting, Barcelona, Spain 8 Amgen (Europe), Zug, Switzerland 9 I-CHER Interuniversity Centre for Health Economics Research, Gent, Belgium
Publication(s):  ISPOR 14th Annual European Congress 5-8 November 2011, Madrid, Spain
Document Type(s): Poster,
Countries: Austria, Italy, Portugal, Spain,
C:
Y:
Oncology,
2011
  L:
A:
English
Cost analysis,
  Add to report
 
 
Cost Analysis of Anaemia Treatment With Erythropoiesis-Stimulating Agents in Cancer Patients Receiving Chemotherapy
Author(s): Duran A1, Spaepen E2, Lamotte M3, Walter E4, Kutikova L5, Pujol B5, Ribnicsek E6, Annemans L7
Affiliations(s): 1IMS Health, London, UK; 2SBD Analytics BVBA/SPRL, Belgium; 3IMS Health, Vilvoorde, Belgium; 4Institut für Pharmaökonomische Forschung, Vienna, Austria; 5Amgen (Europe) GmbH, Zug, Switzerland; 6Amgen, Vienna, Austria; 7I-CHER Interuniversity Centre for Health Economics Research, UGent, VUB, Belgium
Publication(s):  16th Congress of the European Association of Hospital Pharmacists, 30 March - 1 April 2011.
Document Type(s): Poster,
Countries: Austria, Belgium,
C:
Y:
Oncology,
2011
  L:
A:
English
Cost analysis,
  Add to report
 
 
Economic evaluation of Ranibizumab in the treatment of visual impairment due to diabetic macular edema in Austria
Author(s): Brennig C1, Schöllbauer V1, Walter E1, Gallagher M2, Knudsen MS3
Affiliations(s): 1Institute for Pharmaeconomic Research, Vienna, Austria, 2Novartis Pharma AG, Basel, Switzerland, 3IMS Health, London, UK
Publication(s):  ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain
Document Type(s): Poster,
Countries: Austria,
Click here for the abstract
C:
Y:
Diabetes,
2011
  L:
A:
English
Economic evaluation,
  Add to report
 
 
Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study.
Author(s): Jose´ R. Banegas 1,2*, Esther Lo´pez-Garcı´a 1,2, Jean Dallongeville3, Eliseo Guallar 4,5,6,7, Julian P. Halcox8, Claudio Borghi 9, Elvira L. Masso´-Gonza´lez 10, Francisco J. Jime´nez 11, Joep Perk12, Philippe Gabriel Steg13, Guy De Backer 14,and Fernando Rodrı´guez-Artalejo1,2
Affiliations(s): 1 Department of Preventive Medicine and Public Health, School of Medicine, Universidad Auto´noma de Madrid/IdiPAZ, Avda Arzobispo Morcillo, 2, 28029 Madrid, Spain; 2 CIBER of Epidemiology and Public Health, Madrid, Spain; 3 Inserm U 744, Institut Pasteur de Lille, 59019 Lille Cedex, France; 4 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 5 Department of Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 6 Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 7 Department of Cardiovascular Epidemiology and Population Genetics, National Center for Cardiovascular Research (CNIC), Madrid 28029, Spain; 8 Wales Heart Research Institute, Cardiff University, Heath Park, Cardiff CF14 4XN, UK; 9 Department of Internal Medicine, Aging and Clinical Nephrology, University of Bologna, Bologna, Italy; 10Medical Department, AstraZeneca Farmace´utica Spain, S.A., 28003 Madrid, Spain; 11Medical Department, AstraZeneca Europe, 1935 Zaventem, Belgium; 12School of Health and Caring Sciences, Linnaeus University, 391 82 Kalmar, Sweden; 13INSERM U 698, Assistance Publique–Hoˆpitaux de Paris and Universite´ Paris-Diderot, Paris, France; and 14Department of Public Health, University of Gent, 9000 Gent, Belgium
Publication(s):  Eur Heart J. 2011 Sep;32(17):2143-52
Document Type(s): Article,
Countries: Austria, Belgium, France, Germany, Greece, Norway, Spain, Sweden, Switzerland, Turkey, UK,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2011
  L:
A:
English
Observational study, Prospective study,
  Add to report
 
 
Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study.
Author(s): Guallar E, Banegas JR, Blasco-Colmenares E, Jiménez FJ, Dallongeville J, Halcox JP, Borghi C, Massó-González EL, Tafalla M, Perk J, De Backer G, Steg PG, Rodríguez-Artalejo F.
Affiliations(s): 
Publication(s):  BMC Public Health. 2011 Sep 18;11:704. doi: 10.1186/1471-2458-11-704.
Document Type(s): Article,
Countries: Austria, Belgium, France, Germany, Greece, Norway, Russian Federation, Spain, Sweden, Switzerland, Turkey, UK,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2011
  L:
A:
English
Observational study, Prospective study,
  Add to report
 
 
Real-Life Cost Analysis of Anemia Treatment with Erythropoiesis Stimulating Agents In Cancer Patients Receiving Chemotherapy
Author(s): Duran A1, Spaepen E2, Lamotte M3, Walter E4, Kutikova L5, Pujol B5, Annemans L6
Affiliations(s): 1 IMS Health, London, UK; 2 SBD Analytics BVBA/SPRL, Belgium; 3 IMS Health, Brussels, Belgium; 4 Institut fuer Pharmacoekonomische Forschung, Vienna, Austria; 5 Amgen (Europe) GmbH, Zug, Switzerland; 6 I-CHER Interuniversity Centre for Health Economics Research, Gent, Belgium
Publication(s):  American Society of Hematology. December 4-7, 2010 Orlando, FL. USA
Document Type(s): Poster,
Countries: Austria,
C:
Y:
Oncology,
2010
  L:
A:
English
Cost analysis,
  Add to report
 
 
Pharmacoeconomic evaluation of ranibizumab in the treatment of age-related macular degeneration in Austria.
Author(s): Walter E, Brennig C, Moeremans K, Thomas V
Affiliations(s): 
Publication(s):  ISPOR 11th Annual International Meeting, 2008, November 8-11, Athens, Greece
Document Type(s): Poster,
Countries: Austria,
C:
Y:
Ophthalmology,
2008
  L:
A:
English
Cost utility,
  Add to report
 
 
 1 of 2 Next Page Last Page